AstraZeneca sees $4B in COVID-19 vaccine sales
Drugmaker said in November that it would begin to take a 'modest' profit from the shot
AstraZeneca recorded a big jump in revenue on Thursday as it begins to take a profit from its coronavirus vaccine for the first time.
The company recorded full-year revenues of $37.4 billion, an increase of 38% from the year before at constant exchange rates. Part of the boost came from $4 billion in sales of its COVID-19 vaccine, developed with the University of Oxford.
ASTRAZENECA ASKS FDA TO AUTHORIZE COVID ANTIBODY TREATMENT
Despite rising revenue, AstraZeneca reported a pre-tax loss of $265 million due to costs from its purchase of U.S. drug company Alexion Pharmaceuticals and new drug research.
The Anglo-Swedish drugmaker said in November it would begin to take a "modest" profit from the COVID-19 shot, which it had been providing "at cost" — around $2 to $3 —following an agreement with Oxford. Other COVID-19 vaccine producers, such as Pfizer and Moderna, have been booking hefty profits on their shots all along.
Dr Tamara Joffe administer a dose of the AstraZeneca COVID-19 vaccine to Mustafa Field of the Faiths Forum, during a pilot project of pop up vaccination drive called Vaxi Taxi in Kilburn, London, Sunday, Feb. 28, 2021. (AP Photo/Alastair Grant)
In the three months to September, the company said revenue jumped by about 50%, to a record $9.9 billion. The increase was due to sales of more than $1 billion in COVID-19 vaccines and the inclusion for the first time of some $1.3 billion worth of revenue from its rare disease business unit following the recent acquisition of Alexion.
CLICK HERE TO READ MORE ON FOX BUSINESS
| Ticker | Security | Last | Change | Change % |
|---|---|---|---|---|
| AZN | ASTRAZENECA PLC | 63.81 | +0.61 | +0.97% |
AstraZeneca forecast total group sales to rise by a "high teens percentage" in 2022, but said COVID-19 revenues would decline by a "a low-to-mid twenties percentage."
Chief executive Pascal Soriot said AstraZeneca had "delivered on our promise of broad and equitable access to our COVID-19 vaccine with 2.5 billion doses released for supply around the world."
CDC weighs increasing time between vaccine doses to reduce heart inflammation risk
Dr. Bob Lahita, director of the Institute for Autoimmune and Rheumatic Diseases at St. Joseph Health, weighs in, stressing that the 'virus seems to be waning right now.'
"AstraZeneca continued on its strong growth trajectory in 2021, with industry-leading R&D (research and development) productivity, five of our medicines crossing new blockbuster thresholds, and the acquisition and integration of Alexion," he said.
GET FOX BUSINESS ON THE GO BY CLICKING HERE
Soriot said the company would raise the dividend to shareholders by 10 cents to $2.90, the first increase in a decade.
AstraZeneca shares were trading about 3% higher at 8.62 pounds ($11.68) on the London Stock Exchange on Thursday morning.